CA2938126A1 - Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators - Google Patents

Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators Download PDF

Info

Publication number
CA2938126A1
CA2938126A1 CA2938126A CA2938126A CA2938126A1 CA 2938126 A1 CA2938126 A1 CA 2938126A1 CA 2938126 A CA2938126 A CA 2938126A CA 2938126 A CA2938126 A CA 2938126A CA 2938126 A1 CA2938126 A1 CA 2938126A1
Authority
CA
Canada
Prior art keywords
tbk1
nervous system
sympathetic nervous
subject
ikk8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2938126A
Other languages
English (en)
French (fr)
Inventor
Alan R. Saltiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of CA2938126A1 publication Critical patent/CA2938126A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2938126A 2014-02-07 2014-02-07 Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators Abandoned CA2938126A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/015387 WO2015119624A1 (en) 2014-02-07 2014-02-07 COMBINATIONS OF IKKε/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS

Publications (1)

Publication Number Publication Date
CA2938126A1 true CA2938126A1 (en) 2015-08-13

Family

ID=53778306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938126A Abandoned CA2938126A1 (en) 2014-02-07 2014-02-07 Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators

Country Status (6)

Country Link
EP (1) EP3102206A4 (de)
JP (1) JP2017507930A (de)
CN (1) CN106132413A (de)
AU (1) AU2014381711A1 (de)
CA (1) CA2938126A1 (de)
WO (1) WO2015119624A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
EP2991647B1 (de) 2013-05-02 2019-04-24 The Regents Of The University Of Michigan Deuteriertes amlexanox mit verbesserter metabolischer stabilität
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
JP7152051B2 (ja) * 2018-05-29 2022-10-12 株式会社ナノエッグ アトピー性皮膚炎を治療または予防するための組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
EP2437741A1 (de) * 2009-06-01 2012-04-11 Biocopea Limited Verwendung von amlexanox bei der behandlung von neutrophilen-gesteuerten erkrankungen
CA2806825C (en) * 2010-08-05 2018-08-21 Institut Pasteur De Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
ES2659763T3 (es) * 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados

Also Published As

Publication number Publication date
JP2017507930A (ja) 2017-03-23
EP3102206A4 (de) 2017-09-20
EP3102206A1 (de) 2016-12-14
WO2015119624A1 (en) 2015-08-13
CN106132413A (zh) 2016-11-16
AU2014381711A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
Agard et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension
Mowers et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1
Combs et al. Adiponectin signaling in the liver
Zou et al. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4
Edmonds et al. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling
Silveira et al. Activating cAMP/PKA signaling in skeletal muscle suppresses the ubiquitin-proteasome-dependent proteolysis: implications for sympathetic regulation
Aluja et al. Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2
US11278549B2 (en) Method of treating obesity
CN101754687A (zh) 代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗
Fritsche et al. IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise
JP2019116487A (ja) 脂質動員特性を有する糖タンパク質およびその治療的使用法
CA2938126A1 (en) Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators
Muller et al. Overactivation of the endocannabinoid system alters the antilipolytic action of insulin in mouse adipose tissue
WO2019223688A1 (zh) 化合物fg-4592在制备治疗甲状腺激素受体介导疾病及药物制剂中的应用
US20150366865A1 (en) A method of treating obesity
US20150224089A1 (en) COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS
US20200331828A1 (en) Novel compounds which activate estrogen receptors and compositions and methods of using the same
AU2007330607B2 (en) Treatment of cachexia
JP2010518860A (ja) Ｌｙｎキナーゼの活性化剤の同定方法
Haddish et al. L-dihydroxyphenylalanine (L-Dopa) induces brown-like phenotype in 3T3-L1 white adipocytes via activation of dopaminergic and β3-adrenergic receptors
EP3361250B1 (de) Midodrine zur induktion von übungsähnlichen effekten
CN109550051B (zh) 组蛋白去甲基化酶kdm6a抑制剂在制备肥胖症治疗药物的用途
US9370504B2 (en) Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α
WO2017165908A1 (en) Method of inhibiting high fat diet-related conditions
Yu et al. Atractylodin alleviates cancer anorexia-cachexia syndrome by regulating NPY through hypothalamic Sirt1/AMPK axis-induced autophagy

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200207